Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Jason Aryeh sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $320.05, for a total value of $960,150.00. Following the transaction, the director owned 105,476 shares of the company’s stock, valued at $33,757,593.80. This trade represents a 2.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Jason Aryeh also recently made the following trade(s):
- On Wednesday, November 4th, Jason Aryeh sold 282 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $319.99, for a total value of $90,237.18.
- On Monday, November 2nd, Jason Aryeh sold 700 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $320.43, for a total value of $224,301.00.
- On Friday, October 30th, Jason Aryeh sold 1,411 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $320.24, for a total value of $451,858.64.
Ligand Pharmaceuticals Stock Performance
Ligand Pharmaceuticals stock opened at $316.27 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19. The stock has a fifty day moving average price of $301.33 and a two-hundred day moving average price of $257.45. Ligand Pharmaceuticals Incorporated has a 52-week low of $175.89 and a 52-week high of $326.63. The firm has a market capitalization of $6.33 billion, a P/E ratio of 141.19, a P/E/G ratio of 5.53 and a beta of 1.16.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on LGND shares. Leerink Partners initiated coverage on shares of Ligand Pharmaceuticals in a report on Friday, August 14th. They set an “outperform” rating and a $330.00 price target for the company. Royal Bank Of Canada upped their price objective on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Barclays raised their price objective on shares of Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday. Oppenheimer reiterated an “outperform” rating and issued a $326.00 target price (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday, August 3rd. Finally, Weiss Ratings downgraded Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a report on Monday, November 2nd. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $355.38.
Read Our Latest Research Report on LGND
Institutional Trading of Ligand Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in LGND. Ranger Investment Management L.P. bought a new position in shares of Ligand Pharmaceuticals in the second quarter valued at about $81,424,000. Bank of New York Mellon Corp bought a new stake in Ligand Pharmaceuticals during the 2nd quarter worth about $41,429,000. William Blair Investment Management LLC bought a new stake in Ligand Pharmaceuticals during the 3rd quarter worth about $37,264,000. Bessemer Group Inc. grew its holdings in Ligand Pharmaceuticals by 358.8% during the 1st quarter. Bessemer Group Inc. now owns 107,859 shares of the biotechnology company’s stock worth $21,535,000 after acquiring an additional 84,349 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Ligand Pharmaceuticals by 41.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 170,089 shares of the biotechnology company’s stock worth $53,131,000 after acquiring an additional 49,785 shares during the last quarter. 91.28% of the stock is currently owned by institutional investors and hedge funds.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
See Also
- Five stocks we like better than Ligand Pharmaceuticals
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
